Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HK1 | P19367 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465472 | 0.91 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTHK1HKDC1 | |
| SCHEMBL1466273 | 0.91 | PTGDR2 (0.54) | PTGDR2PTGDRAKR1B1 | |
| SCHEMBL3721644 | 0.87 | MAPT (0.44) | ALDH1A1LMNAMAPTHK1HKDC1 | |
| SCHEMBL1465369 | 0.87 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTHK1HKDC1 | |
| SCHEMBL1466781 | 0.87 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTHK1HKDC1 | |
| SCHEMBL1465979 | 0.86 | PTGDR2 (0.46) | ALDH1A1LMNAMAPTHK1HKDC1 | |
| SCHEMBL1465051 | 0.85 | PTGDR2 (0.51) | ALDH1A1LMNAMAPTHK1HKDC1 | |
| SCHEMBL3724053 | 0.85 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPTHK1HKDC1 | |
| SCHEMBL1465686 | 0.84 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTHK1HKDC1 | |
| SCHEMBL1467731 | 0.82 | PTGDR2 (0.52) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-8394836-B2 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| EP-2327693-A1 | Indoles and their therapeutic use | Pulmagen Therapeutics (Asthma) Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | GB005, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2229358-A1 | INDOLES AND THEIR THERAPEUTIC USE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077728-A1 | INDOLES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | IDO2, IDO1, RORB | ALDH1A1 1047/4885LMNA 4560/4885MAPT 3223/4885 |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | FPR3, HRH2, HRH4 | ALDH1A1 1510/4885LMNA 4764/4885MAPT 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.